Oncocyte Announces Market Entry and Early Adopter Program for Transplant Rejection Monitoring Business
13 juil. 2022 08h00 HE
|
Oncocyte Corporation
Oncocyte enters $2B US transplant monitoring market with newly branded VitaGraft™ patented dd-cfDNA technology in two indications, Kidney and Liver Oncocyte initiates IVD Kit Development Process with...
Oncocyte Presents DetermaIO™ Data in Podium Presentation at ESMO World Congress on Gastrointestinal Cancer 2022
06 juil. 2022 08h00 HE
|
Oncocyte Corporation
Researchers conducted exploratory analysis to find an optimized IO score after validation of original established endpoint was presented at the 2022 ASCO Annual Meeting DetermaIO may help to...
Oncocyte Hosting Key Opinion Webinar on the Role of DetermaIO and the Tumor Microenvironment in Clinical Practice
22 juin 2022 08h00 HE
|
Oncocyte Corporation
IRVINE, Calif., June 22, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), is a precision diagnostics company with the mission to improve patient outcomes by providing personalized...
Oncocyte Presents DetermaIO™ Data at ASCO 2022 Supporting the Test’s Potential to Expand the Clinical Use of Immunotherapy
26 mai 2022 17h00 HE
|
Oncocyte Corporation
DetermaIO identifies responders to immunotherapy among the 95% of patients with colon cancer currently ineligible for treatment based on existing biomarker, addressing a significant unmet need ...
Oncocyte Reports First Quarter 2022 Financial Results
11 mai 2022 16h05 HE
|
Oncocyte Corporation
IRVINE, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights...
Oncocyte Completes Validation of TheraSure™ Transplant Monitor Test
05 mai 2022 08h00 HE
|
Oncocyte Corporation
IRVINE, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights...
Oncocyte to Announce First Quarter 2022 Financial Results
28 avr. 2022 16h01 HE
|
Oncocyte Corporation
IRVINE, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights...
Oncocyte to Present New Data at ASCO 2022 Underpinning Pan-Cancer Clinical Utility of DetermaIO™
27 avr. 2022 16h30 HE
|
Oncocyte Corporation
IRVINE, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights...
Oncocyte Corporation Announces Pricing of Public Offering of Common Stock and Warrants
13 avr. 2022 22h01 HE
|
Oncocyte Corporation
IRVINE, Calif., April 13, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), (“Oncocyte” or the “Company”), announced today the pricing of an underwritten public offering of 26,266,417...
Oncocyte Corporation Announces Proposed Public Offering of Common Stock and Warrants
13 avr. 2022 17h12 HE
|
Oncocyte Corporation
IRVINE, Calif., April 13, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), (“Oncocyte” or the “Company”), announced today that it has commenced an underwritten public offering of shares...